Abstract
Introduction: Chimeric antigen receptor T (CAR-T) cells targeting CD19 result in durable responses in approximately 40% of DLBCL patients. Loncastuximab tesirine, an antibody drug conjugate targeting CD19 with a pyrrolobenzodiazepine payload, has activity against DLBCL. Patients and Methods: We evaluated the outcomes of 13 DLBCL patients relapsed after CAR-T cells treated with loncastuximab in the LOTIS-2 trial. Results: Six patients (46%) had responses to loncastuximab (CR, n = 2). Median OS, PFS and duration of response after loncastuximab were 8.2, 1.4 and 8 months, respectively. Conclusion: Loncastuximab can achieve responses in patients progressing after CAR-T cells. Sequencing CD19-targeting therapies is possible in cases without CD19 loss.
Original language | English (US) |
---|---|
Pages (from-to) | e335-e339 |
Journal | Clinical Lymphoma, Myeloma and Leukemia |
Volume | 22 |
Issue number | 5 |
DOIs | |
State | Published - May 2022 |
Keywords
- CAR-T cell failures
- Diffuse large B cell lymphoma
ASJC Scopus subject areas
- Hematology
- Oncology
- Cancer Research